How is ACE-031 (ACVR2B-Fc) administered?
This describes how ACE-031 (ACVR2B-Fc) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly to once monthly in trials schedule, generally over historically tested in short courses. Specific dosing is individual and beyond general information, and human evidence for ACE-031 (ACVR2B-Fc) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly to once monthly in trials
- Cycle length: Historically tested in short courses
- Half-life: ~10-15 days
References
- ACE-031 (soluble activin receptor IIB) increases muscle mass, Phase 1 in postmenopausal women — Attie KM et al., Muscle Nerve, 2013
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial — Campbell C, McMillan HJ, Mah JK, et al., Muscle & Nerve, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ACE-031 (ACVR2B-Fc)
Full ACE-031 (ACVR2B-Fc) breakdownACE-031 (ACVR2B-Fc) what it's used forACE-031 (ACVR2B-Fc) side effectsACE-031 (ACVR2B-Fc) mistakes to avoidACE-031 (ACVR2B-Fc) who should avoid itACE-031 (ACVR2B-Fc) half-lifeACE-031 (ACVR2B-Fc) how long to workACE-031 (ACVR2B-Fc) legal statusACE-031 (ACVR2B-Fc) how it worksAsk the AI Coach
Last updated 2026-06-15.